Your Health, We Care
In recent years, the combination therapy of Vemurafenib with other drugs has also received widespread attention. For example, combination use with MEK inhibitors such as Trametinib can safely eliminate or delay resistance in some patients and improve treatment efficacy.
The Moffett Cancer Center and other institutions have achieved significant results in the clinical trials of Vemurafenib and shared their experience and data with other international research institutions.
